Intermittent Claudication – Pipeline Review, H2 2016 has recently announced the addition of a market study “ Intermittent Claudication – Pipeline Review, H2 2016 , is a comparative analysis of the global market.

Intermittent Claudication – Pipeline Review, H2 2016


Global Markets Directs, Intermittent Claudication – Pipeline Review, H2 2016, provides an overview of the Intermittent Claudication pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Intermittent Claudication, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Intermittent Claudication and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Download The sample Copy Of This Report:


– The report provides a snapshot of the global therapeutic landscape of Intermittent Claudication

– The report reviews pipeline therapeutics for Intermittent Claudication by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Intermittent Claudication therapeutics and enlists all their major and minor projects

– The report assesses Intermittent Claudication therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Intermittent Claudication

Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

– Identify and understand important and diverse types of therapeutics under development for Intermittent Claudication

– Identify potential new clients or partners in the target demographic

– Develop strategic initiatives by understanding the focus areas of leading companies

– Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics

– Devise corrective measures for pipeline projects by understanding Intermittent Claudication pipeline depth and focus of Indication therapeutics

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Intermittent Claudication Overview 6

Therapeutics Development 7

Pipeline Products for Intermittent Claudication – Overview 7

Intermittent Claudication – Therapeutics under Development by Companies 8

Intermittent Claudication – Pipeline Products Glance 9

Clinical Stage Products 9

Early Stage Products 10

Intermittent Claudication – Products under Development by Companies 11

Intermittent Claudication – Companies Involved in Therapeutics Development 12

ID Pharma Co., Ltd. 12

Kowa Company, Ltd. 13

Nuo Therapeutics, Inc. 14

Pluristem Therapeutics Inc. 15

Intermittent Claudication – Therapeutics Assessment 16

Assessment by Monotherapy Products 16

Assessment by Target 17

Assessment by Mechanism of Action 19

Assessment by Route of Administration 21

Assessment by Molecule Type 23

Drug Profiles 25

ALD-301 – Drug Profile 25

Product Description 25

Mechanism Of Action 25

About us is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Read our latest Press Releases at


Mr. Nachiket

State Tower

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA: Canada Toll Free: 866-997-4948



Follow us on LinkedIn: